ADC Therapeutics SA of Switzerland has appointed David Gilman to the new role of chief business and strategy officer, effective 1 July. In this position, he will oversee business development for the company’s antibody-drug conjugates, the first of which was approved by the US Food and Drug Administration in 2021. Mr Gilman joins from the consulting firm ClearView Healthcare Partners. Before that, he was global head of portfolio strategy and business development at Novartis Oncology. Mr Gilman holds an MBA from the University of Texas, Austin and a BA from the University of Chicago, both in the US.
ADC Therapeutics announced the appointment on 13 June 2022
Copyright 2022 Evernow Publishing Ltd